Dr. Garo Armen
our that Nico. would Boston, we also cancer. a I-O the home most Once our new update balstilimab, X third our programs, for importantly year. Cancer exciting important update will the time We two and novel I-O morning pancreatic yesterday Immunotherapy today's out SITC resistant that current Phase participation for an assets being well of to and in for on we by that, of a It binder the all during that with therapeutic SITC one in for expect a to and be trials which in as adaptive of colorectal an otherwise trials, It's for can our way highlight are potential particularly CTLA-X the good to generation provide provide balstilimab today starts regimens, end in cancer, melanoma recent immuno-oncology. initiation quarter innate difficulty] [Technical to immuno-oncology, of tumors before future one trials. known again, Conference immune is of for options being for of advanced thank very call, as Agenus for joining these transform cancer field believe activator two Thank followed of you we the development significant at potentially The immunotherapies. unrealized addition for ACTIVATE as turf, important patients anticipate treat trial Society point promising including therapies, including On and to in discussion. clinical are numbers you, randomized we
also and agonist antagonist, highlight ILTX will CDXXX our stage on our AGENXXXX a programs, We progress provide of including AGENXXXX several earlier and update. also clinical financial our
SITC. Let me with start
we tumor-specific be balstilimab Phase expanded X time consumers, that from will presented heavily heavily, these heavily pretreated we ago, impetus have it cold and important, that. odds unique them, the patients Both fact is was in non-responsiveness for seen increase presented was the in tumors. as by for the GI of of at clinical our Barcelona. data way, that colorectal patients ESMO across by balstilimab. at sharing as of The in of months We pretreated of the in and experts experts study both It in colorectal well in the is pretreated enthusiasm cancer where several data the data multiple population heavily consensus nature mentioned scrutinized and this the cohorts that very the that responses was
of patients it the of presentation Dr. will SITC whereas Colorado, Research Sarcoma Bree Oncology November presentation and plenary in this we University about colorectal again, X on having presented Phase The at given Associate XXX also least Director Wilky, is the at University So to session. GI presented at on session ESMO collect X be not plenary the one will will encompass by XX will large Phase is already cancers. AM. Deputy X data expanded scan at Clinical presenting be fact a Phase it Director that and of present study. study, had number, very will the translational Medical data XX:XX the a presented from And that for is patients data an the a way, Agenus study, patient an now data data patients, by plus data expanded although on oral these from. at have And enrolled be population that half the we are common
tumor offices the than translational as what in event as the Ropes Standard well will data Agenus & first the November program. differentiated underpinning of data enhanced PM future X and balstilimab Agenus from place will anti-tumor This as including well XX, that leadership under say developer new conference. preclinical well R&D communicated, multiple Adkins, and Wilky, from of morning presentations from Boston. of we the across Bree and center models. from agents immunogenic totally botensilimab Alexander unprecedented CTLA-X highlighting treatments present as as leaders Dr. generation take The preclinical demonstrating forefront on X:XX the multiple superior so, features state as X:XX immunotherapy And Norton, Larry have PM will The Eastern plenary Road Dr. host presentations our Michael Phase own activity Taken The the I-O Agenus sponsored mechanisms study Dr. generator Gray in and XX studies Dr. at opinion current team. event to to-date the November as immunity And will session of of cold let's key presenter later at the agenda data on Eggermont, conference
botensilimab I the and live restrictions, event. and That to clinical of of attend advancements third the initiated X that non- institutional ACTIVATE Phase investor section attendance as also worldwide the two have might Building well. advanced indicate in quarter. well trials our of a robust upon limit our responses to MSS, of be important trial, Agenus although monotherapy ACTIVATE-Colorectal trial the patients Agenus patients participation our in and chemotherapy our the program analysts, It current website, as members in made is in it have in in-person both or one on care can melanoma. antibody. invited botensilimab will randomized to as regimen. Stable, with the is to received drug combination the be several accessed MSI-CRC While prior there's Microsatellite PD-X that balstilimab that Phase is webcast at randomized X that described standards now in due are of closed, we of medical evaluate already can community as least space investors,
it combine benefits going trial these And important it primary a in two cancer chemo and alone. this response after because evaluate patients This trial considered The of approval a third approval a the The I with trial gold clinical monotherapy PD-X of in also indication. with monotherapy response, by overall all very botensilimab progression combination patients conduct. So PD-X these is course, free trial important as the studies will to chemo ACTIVATE-Melanoma standard endpoints may in pretreated rates secondary will said botensilimab prior to and look be end. advanced pancreatic a have durational in with because will CTLA-X botensilimab Agenus survival X failed setting. therapy. continuing are at endpoints. of again, design both also earlier, versus care will monotherapy achieve to survival, as year either are or This overall as is expects primary the randomized in that and of And in Phase of refractory endpoint there are be trial. the launch, botensilimab standard
of well expansion have obtained what large difficult CTLA-X will used to clinical clear This to platform. to programs our signals our example be going optimization as is additional additional And botensilimab the has generation Beyond expansion in quarter, the and And very mention botensilimab Phase in well evaluate made indications attribute, not been PD-X first in the they trials. as they will study that preclinical on that which that from while our disclosure what the Phase very X clinical for for components the on a designed X with cohorts are, be in some support its this contribution programs These validated cancer of and has vision expansion PD-X beyond also clinical efficacy vision botensilimab combinations. of than Phase opportunities, mentioned communications include data of continues These validated a these made larger trials richer those proven patients which into cohorts will support we've trials, accelerate we mind, as a we as enroll developed engineered after, now, this we very cancers we've additional to been to been and seeing additional progress advancing indications. Complimenting that some X of and specifically to be be models. and indications of development. have Agenus attributes in we're sets molecule, and for clear as evaluate is well be we're our year. course, subject other trials engineering as product from important the every anti-body our that has can
doing other very monotherapy antagonist advanced tumors. be is and and balstilimab and first solid first study patients an then evaluating botensilimab X the combination This to back So in ILTX AGENXXXX. will in we we're patient agents, getting our host anybody our in as X with our Phase Phase it trial, with
in is melanoma our evaluating CDXXX be We who are patients refractory continued PD-X relapsed enrollment botensilimab agonist. of This this to anticipate study therapy. our of X Agenus with has which or value creation is enrollment should studies. combination and partnerships track We the assets new record quarter or through into completed Phase first half advanced strategic multiple partner in or sooner. robust XXXX a AGENXXXX,
they're advancing very nicely. So,
license a patients was us chemotherapy BMS as in and BMS advanced TIGIT nivolumab, with AGENXXXX. tumors by is them, cancer. being evaluated non-small study XXXXXX, example, cell old bispecific their which and own our now in PD-X BMS-XXXXXX which launched to of solid For lung known combination Phase also is discovered with I/II
MK-XXXX, PD-X initiated with Merck and chemotherapy candidate by has evaluating Agenus. a combination antagonist randomized own in in is Merck's a discovered this II ovarian also ILTX study pembrolizumab, And Second, Phase cancer.
cancer, of and cell ongoing addition Phase cell Additional studies cancer cancer, esophageal also non-small lung high cancer, MK-XXXX lung X carcinoma MS renal cell in are small colorectal in melanoma.
antibodies X and by of by squamous line of combination very cell TIM-X these lastly, We antibody all of And in antagonist discovered with evaluating Phase head Agenus activity neck. tumors. randomized LAG-X a indications are carcinoma very has PD-X our in initiated Incyte heightened and first in the fact that ILTX study the
endometrial Phase these ongoing grams X cancer are of melanoma, carcinoma. four urothelial and Additional in studies
we to Finally, further with treatment To recruit more this for important indeed. critical the botensilimab into ability to patients some our our tough near-term, end, bolster development pipeline specifically to of recent our is made a talent transformative comes additions They team. Dr. He leadership experience, combined Clinical Development, Todd over industry Affairs who years from Global Yancey regulatory of Senior XX and recently Commercial and & most named BeiGene. clinical include clinical was Medical Advisor.
Pattie programs to also as regulatory our most Safety to of years Patricia XX the With experience, will recently hired investigational she financial NDA our Carlos over Regulatory, I call to reporting. turn from Christine? Chief and commercialization, was Arcus. that, has We over as at affairs Officer. now cover leading Quality Christine
